DSGN Design Therapeutics Inc

Price (delayed)

$4.36

Market cap

$246.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.05

Enterprise value

$219.06M

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on ...

Highlights
The quick ratio has grown by 30% from the previous quarter and by 9% YoY
DSGN's debt is down by 26% year-on-year and by 8% since the previous quarter
Design Therapeutics's equity has decreased by 14% YoY and by 2.9% QoQ

Key stats

What are the main financial stats of DSGN
Market
Shares outstanding
56.5M
Market cap
$246.32M
Enterprise value
$219.06M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$58.67M
EBITDA
-$58.1M
Free cash flow
-$53.94M
Per share
EPS
-$1.05
Free cash flow per share
-$0.95
Book value per share
$4.77
Revenue per share
$0
TBVPS
$4.94
Balance sheet
Total assets
$278.79M
Total liabilities
$9.24M
Debt
$2.14M
Equity
$269.56M
Working capital
$266.79M
Liquidity
Debt to equity
0.01
Current ratio
38.61
Quick ratio
38.16
Net debt/EBITDA
0.47
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-19.9%
Return on equity
-20.8%
Return on invested capital
-22.5%
Return on capital employed
-21.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DSGN stock price

How has the Design Therapeutics stock price performed over time
Intraday
2.83%
1 week
27.49%
1 month
15.65%
1 year
-36.63%
YTD
64.53%
QTD
30.15%

Financial performance

How have Design Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$70.94M
Net income
-$58.67M
Gross margin
N/A
Net margin
N/A
DSGN's net income is up by 15% YoY and by 12% QoQ
DSGN's operating income is up by 9% since the previous quarter and by 7% year-on-year

Growth

What is Design Therapeutics's growth rate over time

Valuation

What is Design Therapeutics stock price valuation
P/E
N/A
P/B
0.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 16% year-on-year and by 12% since the previous quarter
Design Therapeutics's equity has decreased by 14% YoY and by 2.9% QoQ
DSGN's P/B is 14% above its last 4 quarters average of 0.8

Efficiency

How efficient is Design Therapeutics business performance
The company's return on invested capital rose by 9% QoQ and by 7% YoY
DSGN's ROE is up by 9% QoQ
Design Therapeutics's ROA has increased by 9% from the previous quarter

Dividends

What is DSGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DSGN.

Financial health

How did Design Therapeutics financials performed over time
DSGN's current ratio is up by 31% since the previous quarter and by 10% year-on-year
The quick ratio has grown by 30% from the previous quarter and by 9% YoY
DSGN's debt is 99% smaller than its equity
DSGN's debt is down by 26% year-on-year and by 8% since the previous quarter
Design Therapeutics's equity has decreased by 14% YoY and by 2.9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.